Apixaban CAS 503612-47-3 Raw Powder

Related Attributes

Product details

Apixaban Powder Usage and Synthesis:

Apixaban Powder is an anticoagulant medication that is used to prevent blood clots from forming or to treat existing blood clots in the veins of the legs, lungs, or other parts of the body. It works by inhibiting the activity of a protein called factor Xa, which is involved in the blood clotting process. Apixaban Raw Powder is taken orally in tablet form and is usually prescribed for a period of several months to prevent recurrent blood clots. It is also used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. 

Pharmacokinetics of Apixaban Powder:

Apixaban is a new oral factor Xa inhibitor co-developed by Bristol-Myers Squibb and Pfizer, under the trade name Eladol, is a new oral anticoagulant. On April 26, 2007, Bristol-Myers Squibb and Pfizer announced a collaboration to develop Apixaban, a new oral anticoagulant owned by Bristol-Myers Squibb, as an upgraded alternative to warfarin. 

Under the collaboration agreement, Pfizer will pay Bristol-Myers Squibb an upfront payment of $250 million for 60% of the total development costs of the anticoagulant apixaban (effective January 1, 2007), while Bristol-Myers Squibb will cover the remaining 40%, thereby acquiring co-development and marketing rights for the drug.

In May 2011, apixaban was first approved for use in the EU-27, as well as in Iceland and Norway, for prophylaxis of venous thrombosis in adult patients In the EU-27, as well as in Iceland and Norway, for prophylaxis of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery.

Applications of Apixaban Powder:

Apixaban is an oral selective activation factor X inhibitor that prevents thrombosis but has a lower adverse effect on bleeding than the older drug warfarin, and is used for thromboprophylaxis in patients who have undergone elective hip or knee replacement surgery. Apixaban is the third new oral anticoagulant to be marketed after dabigatran and rivaroxaban. It has been approved in Europe for the prevention of venous thromboembolic events in patients who have undergone elective hip or knee replacement surgery.

Why choose us?

HRK Factory

About Shipping